Skip to main content
PMC home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1982 Oct;50(1):99–106.

Correction of a suppressor cell deficiency in four patients with familial mediterranean fever by in vitro or in vivo colchicine

D Ilfeld, O Kuperman
PMCID: PMC1536837  PMID: 6217006

Abstract

We have previously reported that three patients with familial Mediterranean fever (FMF) had deficient concanavalin A (Con A) activated suppressor cell inhibition of the proliferation of healthy volunteers' phytohaemagglutinin stimulated responder cells. When these three FMF patients were treated with long term oral colchicine (2 mg/day), their Con A activated suppressor cell deficiency was corrected and FMF attacks prevented. In the present report, the effect of in vitro as well as in vivo colchicine treatment on the suppressor cell function of these three FMF patients as well as one more FMF patient was tested to determine whether colchicine can directly increase suppressor cell function rather than colchicine's preventing FMF attacks by unknown mechanisms which only indirectly results in a correction of the suppressor cell deficiency. Long term oral colchicine treatment corrected the suppressor cell deficiency in the four FMF patients (5±2%, 35±5%, and 46±4% for mean ±s.e.m.% suppression for 0, 1 and 2 mg/day of oral colchicine, respectively). Oral colchicine treatment corrected their suppressor cell deficiency within one week of commencing treatment and even corrected one of the FMF patient's suppressor cell deficiency while he still had some FMF attacks on 1 mg/day of colchicine. Suppressor cells from two of the in vivo untreated FMF patients cultured with 10-5 M colchicine plus Con A significantly (P<0·01) suppressed proliferation (36±5%) as compared to their suppressor cells cultured only with Con A (4±7%). Furthermore, these in vivo untreated FMF patients' suppressor cells cultured with 10-5 M colchicine (without Con A) often suppressed as compared to their suppressor cells cultured in medium. Thus colchicine appears to directly correct these FMF patients' suppressor cell deficiency. These observations raise the possibility that colchicine may be therapeutically useful in treating patients with other diseases associated with an absolute or relative deficiency of suppressor cell function.

Full text

PDF
100

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Fulton A. M., Levy J. G. The induction of nonspecific T suppressor lymphocytes by prostaglandin E1. Cell Immunol. 1981 Mar 15;59(1):54–60. doi: 10.1016/0008-8749(81)90433-0. [DOI] [PubMed] [Google Scholar]
  2. Gelfand E. W., Dosch H. M., Hastings B., Shore A. Lithium: a modulator of cyclic AMP-dependent events in lymphocytes? Science. 1979 Jan 26;203(4378):365–367. doi: 10.1126/science.216075. [DOI] [PubMed] [Google Scholar]
  3. Gemsa D., Kramer W., Brenner M., Till G., Resch K. Induction of prostaglandin E release from macrophages by colchicine. J Immunol. 1980 Jan;124(1):376–380. [PubMed] [Google Scholar]
  4. Gemsa D., Steggemann L., Till G., Resch K. Enhancement of the PGE1 response of macrophages by concanavalin A and colchicine. J Immunol. 1977 Aug;119(2):524–529. [PubMed] [Google Scholar]
  5. Gupta S., Schwartz S. A., Good R. A. Subpopulations of human T lymphocytes. VII. Cellular basis of concanavalin A-induced T cell-mediated suppression of immunoglobulin production by B lymphocytes from normal humans. Cell Immunol. 1979 May;44(2):242–251. doi: 10.1016/0008-8749(79)90002-9. [DOI] [PubMed] [Google Scholar]
  6. Hodgson H. J., Wands J. R., Isselbacher K. J. Alteration in suppressor cell activity in chronic active hepatitis. Proc Natl Acad Sci U S A. 1978 Mar;75(3):1549–1553. doi: 10.1073/pnas.75.3.1549. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Ilfeld D. N., Weil S., Kuperman O. Suppressor cell function in a family with familial Mediterranean fever. Clin Exp Immunol. 1981 Feb;43(2):357–361. [PMC free article] [PubMed] [Google Scholar]
  8. Ilfeld D., Weil S., Kuperman O. Correction of a suppressor cell deficiency and amelioration of familial Mediterranean fever by hemodialysis. Arthritis Rheum. 1982 Jan;25(1):38–41. doi: 10.1002/art.1780250106. [DOI] [PubMed] [Google Scholar]
  9. Ilfeld D., Weil S., Kuperman O. Correction of nonsuppressible responder cells by colchicine in familial Mediterranean fever. Arthritis Rheum. 1982 Apr;25(4):471–472. doi: 10.1002/art.1780250421. [DOI] [PubMed] [Google Scholar]
  10. Ilfeld D., Weil S., Kuperman O. Immunoregulatory abnormalities in familial Mediterranean fever. Clin Immunol Immunopathol. 1981 Feb;18(2):261–267. doi: 10.1016/0090-1229(81)90032-5. [DOI] [PubMed] [Google Scholar]
  11. Kawanishi H., Tavassolie H., MacDermott R. P., Sheagren J. N. Impaired concanavalin A-inducible suppressor T-cell activity in active alcoholic liver disease. Gastroenterology. 1981 Mar;80(3):510–517. [PubMed] [Google Scholar]
  12. Kershenobich D., Uribe M., Suárez G. I., Mata J. M., Pérez-Tamayo R., Rojkind M. Treatment of cirrhosis with colchicine. A double-blind randomized trial. Gastroenterology. 1979 Sep;77(3):532–536. [PubMed] [Google Scholar]
  13. Krakauer R. S., Sundeen J., Sauder D. N., Scherbel A. Abnormalities of immunoregulation in progressive systemic sclerosis. Evidence for excess helper-cell function and altered B-cell function. Arch Dermatol. 1981 Feb;117(2):80–82. [PubMed] [Google Scholar]
  14. Loor F. Binding and redistribution of lectins on lymphocyte membrane. Eur J Immunol. 1974 Mar;4(3):210–220. doi: 10.1002/eji.1830040311. [DOI] [PubMed] [Google Scholar]
  15. Raupp L. C., Lum L. G., Oppenheim J. J., Blaese R. M., Olson D., Smith-Gill S. J. Enhanced cAMP production by activated human Fc-IgG receptor positive T-cell subpopulations. Clin Immunol Immunopathol. 1981 Oct;21(1):1–11. doi: 10.1016/0090-1229(81)90189-6. [DOI] [PubMed] [Google Scholar]
  16. Reaman G. H., Poplack D. G., Broder S., Pichler W. J. Fc receptors on human T lymphocytes. V: Effects of colchicine and cytochalasin B on Fc receptor expression. J Immunol. 1980 Nov;125(5):2215–2219. [PubMed] [Google Scholar]
  17. Rola-Pleszczynski M., Blanchard R. Suppressor cell function in respiratory allergy. Modulation by aminophylline and isoproterenol. Int Arch Allergy Appl Immunol. 1981;64(4):361–370. doi: 10.1159/000232717. [DOI] [PubMed] [Google Scholar]
  18. Rudolph S. A., Greengard P., Malawista S. E. Effects of colchicine on cyclic AMP levels in human leukocytes. Proc Natl Acad Sci U S A. 1977 Aug;74(8):3404–3408. doi: 10.1073/pnas.74.8.3404. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Shore A., Dosch H., Gelfand E. W. Induction and separation of antigen-dependent T helper and T suppressor cells in man. Nature. 1978 Aug 10;274(5671):586–587. doi: 10.1038/274586a0. [DOI] [PubMed] [Google Scholar]
  20. Suader D. N., Bailin P. L., Sundeen J., Krakauer R. S. Suppressor cell function in psoriasis. Arch Dermatol. 1980 Jan;116(1):51–55. doi: 10.1001/archderm.116.1.51. [DOI] [PubMed] [Google Scholar]
  21. Wahba A., Cohen H. Therapeutic trials with oral colchicine in psoriasis. Acta Derm Venereol. 1980;60(6):515–520. [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES